EMEA-003273-PIP02-22 - paediatric investigation plan

cobolimab

Key facts

• Active Substance:
  cobolimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0480/2023
• PIP number:
  EMEA-003273-PIP02-22
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of all conditions included in the category of malignant neoplasms including lymphoma
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  GlaxoSmithKline Trading Services Limited

  email: [e-mail]; tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  01/12/2023

Decision

P/0480/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for cobolimab (EMEA-003273-PIP02-22)

AdoptedReference Number: EMA/498512/2023